Drew J Winston

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment
    Drew J Winston
    Blood 104:1581; author reply 1582. 2004
  2. ncbi Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
    Francisco M Marty
    Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Infect Dis 11:284-92. 2011
  3. ncbi Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial
    D J Winston
    Department of Medicine, UCLA Center for the Health Sciences, Los Angeles, CA, USA
    Am J Transplant 12:3021-30. 2012
  4. ncbi Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study
    Drew J Winston
    University of California, Los Angeles Medical Center, Los Angeles, CA 90095, USA
    Blood 111:5403-10. 2008
  5. ncbi Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients
    Drew J Winston
    Division of Hematology Oncology, Department of Medicine, UCLA Medical Center, University of California Los Angeles, CA 90095, USA
    Biol Blood Marrow Transplant 17:507-15. 2011
  6. ncbi Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalov
    Drew J Winston
    Department of Medicine, UCLA Medical Center, Los Angeles, CA 90095, USA
    Transplantation 77:305-8. 2004
  7. ncbi Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial
    Drew J Winston
    Department of Medicine, UCLA Medical Center, Room 42 121 CHS, 10833 Le Conte Avenue, Los Angeles, California 90095, USA
    Ann Intern Med 138:705-13. 2003
  8. ncbi Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation
    Drew J Winston
    University of California, Center for the Health Sciences, Los Angeles, USA
    Clin Infect Dis 36:749-58. 2003
  9. ncbi Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract
    Drew J Winston
    Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, California 90095, and Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA, USA
    Biol Blood Marrow Transplant 12:635-40. 2006
  10. ncbi Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients
    Drew J Winston
    Division of Hematology-Oncology, Department of Medicine, and the Dumont-UCLA Transplant Center, Department of Surgery, UCLA Medical Center, Los Angeles, CA 90095, USA
    Transplantation 75:229-33. 2003

Detail Information

Publications15

  1. ncbi Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment
    Drew J Winston
    Blood 104:1581; author reply 1582. 2004
  2. ncbi Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
    Francisco M Marty
    Brigham and Women s Hospital and Dana Farber Cancer Institute, Boston, MA 02115, USA
    Lancet Infect Dis 11:284-92. 2011
    ..We assessed the safety, tolerability, and antiviral activity of oral maribavir in such patients...
  3. ncbi Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial
    D J Winston
    Department of Medicine, UCLA Center for the Health Sciences, Los Angeles, CA, USA
    Am J Transplant 12:3021-30. 2012
    ..At a dose of 100 mg twice daily, maribavir is safe but not adequate for prevention of CMV disease in liver transplant recipients at high risk for CMV disease...
  4. ncbi Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study
    Drew J Winston
    University of California, Los Angeles Medical Center, Los Angeles, CA 90095, USA
    Blood 111:5403-10. 2008
    ..Maribavir had no adverse effect on neutrophil or platelet counts. These results show that maribavir can reduce the incidence of CMV infection and, unlike ganciclovir, does not cause myelosuppression...
  5. ncbi Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients
    Drew J Winston
    Division of Hematology Oncology, Department of Medicine, UCLA Medical Center, University of California Los Angeles, CA 90095, USA
    Biol Blood Marrow Transplant 17:507-15. 2011
    ..Thus, strategies to improve posaconazole exposure, including the use of higher doses, administration with an acidic beverage, and restriction of proton pump inhibitors, need to be considered when using prophylactic posaconazole...
  6. ncbi Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalov
    Drew J Winston
    Department of Medicine, UCLA Medical Center, Los Angeles, CA 90095, USA
    Transplantation 77:305-8. 2004
    ....
  7. ncbi Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial
    Drew J Winston
    Department of Medicine, UCLA Medical Center, Room 42 121 CHS, 10833 Le Conte Avenue, Los Angeles, California 90095, USA
    Ann Intern Med 138:705-13. 2003
    ..Because of concerns about fungal resistance with fluconazole and toxicity with amphotericin B, alternative prophylactic regimens have become necessary...
  8. ncbi Randomized comparison of oral valacyclovir and intravenous ganciclovir for prevention of cytomegalovirus disease after allogeneic bone marrow transplantation
    Drew J Winston
    University of California, Center for the Health Sciences, Los Angeles, USA
    Clin Infect Dis 36:749-58. 2003
    ..943; 95% CI, 0.176-21.44; P=.588). Oral valacyclovir can be an effective alternative to intravenous ganciclovir for prophylaxis of CMV disease after bone marrow transplantation...
  9. ncbi Pharmacokinetics of ganciclovir after oral valganciclovir versus intravenous ganciclovir in allogeneic stem cell transplant patients with graft-versus-host disease of the gastrointestinal tract
    Drew J Winston
    Department of Medicine, University of California Los Angeles Medical Center, Los Angeles, California 90095, and Dana Farber Cancer Institute, Brigham and Women s Hospital, Boston, MA, USA
    Biol Blood Marrow Transplant 12:635-40. 2006
    ..48%-118.02%). Oral valganciclovir could be a useful alternative to intravenous ganciclovir in certain stable stem cell transplant patients who require prophylaxis or preemptive therapy for cytomegalovirus infection...
  10. ncbi Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients
    Drew J Winston
    Division of Hematology-Oncology, Department of Medicine, and the Dumont-UCLA Transplant Center, Department of Surgery, UCLA Medical Center, Los Angeles, CA 90095, USA
    Transplantation 75:229-33. 2003
    ..This superior protection against CMV disease extends up to 1 year after transplantation and is not associated with ganciclovir resistance...
  11. ncbi Treatment of Scedosporium apiospermum brain abscesses with posaconazole
    Ingo K Mellinghoff
    Division of Hematology-Oncology, Department of Medicine, University of California Los Angeles School of Medicine, Los Angeles, CA, 90095, USA
    Clin Infect Dis 34:1648-50. 2002
    ..The infection progressed despite neurosurgical drainage and treatment with itraconazole, amphotericin B, and ketoconazole, but the brain abscesses completely resolved after treatment with posaconazole alone...
  12. ncbi Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
    Oliver A Cornely
    University of Cologne, Cologne, Germany
    N Engl J Med 356:348-59. 2007
    ..Patients with neutropenia resulting from chemotherapy for acute myelogenous leukemia or the myelodysplastic syndrome are at high risk for difficult-to-treat and often fatal invasive fungal infections...
  13. ncbi [Antifungal prophylaxis in allogenic hematopoietic stem-cell transplant recipients]
    Yuzuru Kanakura
    Jpn J Antibiot 57:421-4. 2004
  14. ncbi Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients
    Drew J Winston
    Transplantation 74:688-95. 2002
    ..Except for gastrointestinal side effects, oral itraconazole solution is well tolerated and has no significant hepatotoxicity...
  15. ncbi Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever
    Thomas J Walsh
    National Cancer Institute, Bethesda, MD 20892, USA
    N Engl J Med 346:225-34. 2002
    ..17) but by two days in patients at high risk (P=0.03). CONCLUSIONS: Voriconazole is a suitable alternative to amphotericin B preparations for empirical antifungal therapy in patients with neutropenia and persistent fever...